HUTCHMED (China) (HCM) EBITDA Margin (2015 - 2021)

HUTCHMED (China) (HCM) posted quarterly EBITDA Margin of 42.81% for Q4 2021, down 115.36% quarter-over-quarter from 278.72% in Q1 2021.

HUTCHMED (China) (HCM) EBITDA Margin (2015 - 2021) Analysis & Trends

HUTCHMED (China) (HCM) has reported EBITDA Margin for 6 consecutive years, with 42.81% the latest figure, recorded in Q4 2021.

In Q4 2021, EBITDA Margin changed N/A year-over-year to 42.81%; the TTM figure through Dec 2021 stood at 113.79% (changed N/A YoY), while the FY2025 annual figure was 145.82%, up 249429.0% from the prior year.
EBITDA Margin slipped to 42.81% in Q4 2021 per HCM's latest filing, from 278.72% in the prior quarter.
Across five years, EBITDA Margin topped out at 278.72% in Q1 2021 and bottomed at 303.37% in Q4 2018.
Historically, EBITDA Margin has averaged 15.53% across 4 years, with a median of 8.83% in 2021.
Annual changes were most pronounced in 2019 — EBITDA Margin tumbled 37387 bps — and 2020, when it jumped 35203 bps.
HUTCHMED (China)'s EBITDA Margin stood at 303.37% in 2018, then surged by 76 bps to 72.05% in 2019, then surged by 289 bps to 136.04% in 2020, then slumped by 131 bps to 42.81% in 2021.
Business Quant data shows HCM's EBITDA Margin at 42.81% in Q4 2021, 278.72% in Q1 2021, and 136.04% in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	-5.58%
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	33.91%
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	16.51%
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	42.23%
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	0.17%
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	15.80%
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	18.13%
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	HUTCHMED (China)	2.18 Bn	2.18 Bn	-	-

Download Data